More than 6 million Americans suffer from chronic heart failure. The disease gradually weakens the heart muscle, destroying its ability to pump enough oxygen and blood to other organs.
But the results of the largest clinical trial of its kind, which so far relied heavily on drugs that act on the heart’s complex neurohormonal pathways, have done little to reduce mortality in the time it has been taking in diseases. Give hope to the patient.
Texas Heart Institute physicians and scientists show that a new approach using cell therapy to combat inflammation, one of the leading causes of heart failure, could have a dramatic impact on patient outcomes. I was.
The Phase 3 DREAM-HF trial was conducted at 51 centers in 565 patients receiving medication for chronic heart failure, non-placebo recipients receiving transendocardial administration of mesenchymal progenitor cells (MPCs). I underwent a baseline and 12-month echocardiogram. gone.
Patients receiving MPC cells, derived from the bone marrow of healthy donors and developed by the Australian biotechnology company Mesoblast, significantly strengthened the left ventricular muscle and its pumping capacity in the first 12 months. Thirty months after initial treatment, MPC therapy reduced the incidence of heart attack or stroke by 58%, rising to 75% for patients with high levels of inflammatory blood markers.
“The DREAM-HF results are an important step in understanding how cell therapy can benefit patients with chronic heart failure due to poor pump function.” It seems to work by increasing the flow of blood and strengthening the heart muscle.”
Texas Heart Institute
Improvements in left ventricular ejection fraction, a measure of the heart’s pumping capacity, are particularly welcome to researchers who believe cell therapy is the next frontier for tackling this cardiovascular disease in patients with high levels of inflammation. It has been proven to be
“The cells appear to have systemic immunomodulatory and anti-inflammatory effects,” Dr. Perrin said. In the great blood vessels throughout the body, reduced inflammation from MPC activation may reduce plaque instability that contributes to heart attack and stroke.”
Heart failure accounts for about 8.5% of deaths from heart disease each year, but its symptoms are often mistaken for normal signs of aging. People with high blood pressure, diabetes, obesity, heart disease, lung disease, and sleep apnea are at increased risk of developing this disease.
“MPC therapy has the potential to change the future of cardiovascular care for patients with inflammatory heart failure,” said Joseph G. Rogers, PhD, CEO and advanced heart failure specialist at the Texas Heart Institute.
This research Journal of the American College of Cardiology.
Source: Texas Heart Institute
